Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) have earned an average recommendation of “Moderate Buy” from the eleven research firms that are covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, three have issued a hold rating, five have assigned a buy rating and two have issued a strong buy rating on the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $52.7778.

A number of brokerages have weighed in on ARWR. Morgan Stanley boosted their price objective on Arrowhead Pharmaceuticals from $45.00 to $48.00 and gave the company an “equal weight” rating in a research note on Wednesday, November 26th. Royal Bank Of Canada lifted their target price on shares of Arrowhead Pharmaceuticals from $45.00 to $52.00 and gave the company an “outperform” rating in a report on Wednesday, November 19th. HC Wainwright reiterated a “buy” rating and set a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research note on Wednesday, October 8th. Bank of America raised their price objective on shares of Arrowhead Pharmaceuticals from $42.00 to $62.00 and gave the stock a “buy” rating in a research report on Monday. Finally, Piper Sandler lifted their price objective on shares of Arrowhead Pharmaceuticals from $45.00 to $70.00 and gave the company an “overweight” rating in a research note on Wednesday, November 19th.

Insider Activity

In other Arrowhead Pharmaceuticals news, Director Mauro Ferrari sold 8,750 shares of Arrowhead Pharmaceuticals stock in a transaction that occurred on Friday, November 28th. The stock was sold at an average price of $56.39, for a total value of $493,412.50. Following the transaction, the director directly owned 68,764 shares in the company, valued at approximately $3,877,601.96. This trade represents a 11.29% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, insider James C. Hamilton sold 20,000 shares of the business’s stock in a transaction that occurred on Wednesday, October 1st. The shares were sold at an average price of $35.00, for a total value of $700,000.00. Following the completion of the transaction, the insider directly owned 212,122 shares in the company, valued at approximately $7,424,270. The trade was a 8.62% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 43,750 shares of company stock worth $1,643,413 in the last 90 days. 4.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Arrowhead Pharmaceuticals

Several institutional investors have recently bought and sold shares of ARWR. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Arrowhead Pharmaceuticals during the 1st quarter worth $174,000. XTX Topco Ltd acquired a new position in shares of Arrowhead Pharmaceuticals during the first quarter worth about $133,000. Vanguard Group Inc. increased its stake in shares of Arrowhead Pharmaceuticals by 8.4% during the first quarter. Vanguard Group Inc. now owns 13,202,562 shares of the biotechnology company’s stock worth $168,201,000 after acquiring an additional 1,018,273 shares during the period. Charles Schwab Investment Management Inc. raised its holdings in Arrowhead Pharmaceuticals by 1.7% during the first quarter. Charles Schwab Investment Management Inc. now owns 1,035,290 shares of the biotechnology company’s stock worth $13,190,000 after purchasing an additional 17,570 shares in the last quarter. Finally, Ontario Teachers Pension Plan Board acquired a new stake in Arrowhead Pharmaceuticals in the first quarter valued at about $583,000. 62.61% of the stock is owned by institutional investors and hedge funds.

Arrowhead Pharmaceuticals Stock Up 6.7%

ARWR opened at $56.25 on Tuesday. Arrowhead Pharmaceuticals has a one year low of $9.57 and a one year high of $59.15. The company has a debt-to-equity ratio of 0.39, a quick ratio of 4.87 and a current ratio of 4.87. The stock has a market capitalization of $7.64 billion, a P/E ratio of -43.95 and a beta of 1.27. The business’s 50-day simple moving average is $39.63 and its 200-day simple moving average is $26.34.

About Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.